COMPUTEX Forum Day 1: Deep Diving into AI and AIoT
According to Gartner, by 2023, one-third of companies that have implemented IoT will also have implemented AI in conjunction with at least one IoT project. Data generated from IoT devices will be integrated in various vertical applications and eventually be applied to smart factories, smart healthcare, smart transportation, and smart cities. The first two sessions of COMPUTEX Forum organized by TAITRA, "AIoT Evolution" and "AI Empowerment,” were held on June 2. Top speakers from Micron Technology, Intel, Supermicro, NVIDIA, NXP Semiconductors, Arm, Delta Electronics, and Check Point Software were among the lineup to deep dive into the infinite possibilities of AIoT and AI.
Micron Technology: Driving AI innovation with storage in the new era of data intensive computing
President and CEO of Micron Technology Sanjay Mehrotra pointed out that the world is at the dawn of a new age of data intensive computing. AI and 5G are the two major drivers of this age. With the rapid growth of AI applications, accompanied by numerous challenges, Micron Technology will continue to build a reliable, systematic infrastructure based on memory and storage for a better AI future.
Intel: Embracing infinite computing possibilities with next-gen AI processor
Nash Palaniswamy, Vice President of Intel’s Sales and Marketing Group and General Manager of AI, HPC, Datacenter Accelerators Solutions and Sales, addressed the possibilities of 3rd Gen Intel Xeon Scalable Processor. The latest generation of Xeon is capable of fulfilling AI and high-performance computing needs. Supported by close partnerships and deep integrations with the world’s software leaders and solution providers, Intel delivers fast, consistent, and secure solutions that people trust.
Supermicro: Meeting demands for innovations with an array of products and solutions
Supermicro President and CEO Charles Liang stated that Supermicro will continue to meet customer demand in terms of AI, 5G, and cloud solutions through its leading technology, innovation, high quality, and serviceability. Supermicro will also push forward the development of technology with its partners through collaborations.
NVIDIA: Igniting Industrial Revolution 4.0 with AI
According to Jerry Chen, NVIDIA Head of Global Business Development for Manufacturing and Industrials, AI is the most impactful general-purpose technology, and it will be at the heart of advanced technologies such as 5G, HPC, AIoT, and robotics, propelling industry development and transformation.
NXP Semiconductors: Accelerating Secure Intelligent Edge with New Era of Edge Computing Started
Kurt Sievers, President and CEO of NXP Semiconductors, indicated that AIoT devices are changing the way people live. While it creates great user experience, it is imperative to fully protect data and realize a secure intelligent edge. NXP Semiconductors will also continue to enable a safer and smarter world through breakthrough innovations.
Arm: Accelerating ubiquitous intelligence
Rene Haas, President of Arm IP Products Group, discussed the increasing global demand for computing. The new Armv9 architecture is effective in addressing demanding AI/ML workloads while delivering enhanced security. The next-gen architecture outlines the roadmap for the next decade of computing.
Intelligence-driven manufacturing for advancing into Industry 4.0
According to Dr. Steven Chen, Leader of Intelligent Mobile Machine Cluster, Delta Research Center of Delta Electronics, manufacturers must continue to improve their capabilities to achieve “Manufacturing on Demand.” By adopting design that incorporate standardized, modular and intelligent units, machines can be more scalable and flexible to production changes, as well as data collection & analysis and AI adoption and upgrade, accelerating the progress of an Intelligence-driven manufacturing.
Check Point Software: Managing cybersecurity risks through AI tool
Kev Hau, Check Point Security evangelist, office of the CTO, shared his insights on the trend of cybersecurity in the new normal. AI, machine learning, and big data analytics are all revolutionizing cybersecurity. The machine-learning algorithm of AI is capable of predicting unknown threats in a much broader scope and providing cybersecurity specialists a quick response with increasing accuracy and precision.
AI is reshaping the world. With the democratization of related technologies and AIoT applications, COMPUTEX aims to explore more business opportunities with its global partners.
- All sessions are available online from now: https://virtual.computextaipei.com.tw/events/
- Register for free:
https://virtual.computextaipei.com.tw/
For more information: https://virtual.computextaipei.com.tw/events/
#########
For more information:
COMPUTEX : https://www.computextaipei.com.tw/
InnoVEX : https://www.innovex.com.tw/
About COMPUTEX
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnovexVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
Explore #COMPUTEXVirtual now at https://virtual.computextaipei.com.tw/.
About TAITRA
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005420/en/
Contact information
Press:
Ms. Tessa Lin <tessalin@taitra.org.tw>
Ms. Li Chao < lichao@taitra.org.tw>
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom